AAAAAA
Results:
1-12
|
Results: 12
Authors:
Virgolini, I
Traub, T
Novotny, C
Leimer, M
Fuger, B
Li, SR
Patri, P
Pangerl, T
Angelberger, P
Raderer, M
Andreae, F
Kurtaran, A
Dudczak, R
Citation: I. Virgolini et al., New trends in peptide receptor radioligands, Q J NUCL M, 45(2), 2001, pp. 153-159
Authors:
Virgolini, I
Patri, P
Novotny, C
Traub, T
Leimer, M
Fuger, B
Li, SR
Angelberger, P
Raderer, M
Wogritsch, S
Kurtaran, A
Kletter, K
Dudczak, R
Citation: I. Virgolini et al., Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr(3)-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy, ANN ONCOL, 12, 2001, pp. S41-S45
Authors:
Li, SR
Koller, E
Valent, P
Gludovacz, D
Yang, Q
Patri, P
Angelberger, P
Dudczak, R
Virgolini, I
Citation: Sr. Li et al., Effects of vasoactive intestinal peptide (VIP) and somatostatin (SST) on lipoprotein receptor expression by A431 tumor cells, LIFE SCI, 68(11), 2001, pp. 1243-1257
Authors:
Li, SR
Peck-Radosavljevic, M
Koller, E
Koller, F
Kaserer, K
Kreil, A
Kapiotis, S
Hamwi, A
Weich, HA
Valent, P
Angelberger, P
Dudczak, R
Virgolini, I
Citation: Sr. Li et al., Characterization of I-123-vascular endothelial growth factor-binding sitesexpressed on human tumour cells: Possible implication for tumour scintigraphy, INT J CANC, 91(6), 2001, pp. 789-796
Authors:
Virgolini, I
Traub, T
Leimer, M
Novotny, C
Pangerl, T
Ofluoglu, S
Halvadjieva, E
Smith-Jones, P
Flores, J
Li, SR
Angelberger, P
Havlik, E
Andreae, F
Raderer, M
Kurtaran, A
Niederle, B
Dubczak, R
Citation: I. Virgolini et al., New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy, Q J NUCL M, 44(1), 2000, pp. 50-58
Authors:
Raderer, M
Kurtaran, A
Leimer, M
Angelberger, P
Niederle, B
Vierhapper, H
Vorbeck, F
Hejna, MHL
Scheithauer, W
Pidlich, J
Virgolini, I
Citation: M. Raderer et al., Value of peptide receptor scintigraphy using I-123-vasoactive intestinal peptide and In-111-DTPA-D-Phe(1)-octreotide in 194 carcinoid patients: Vienna university experience, 1993 to 1998, J CL ONCOL, 18(6), 2000, pp. 1331-1336
Authors:
Pirich, C
Pilger, A
Schwameis, E
Germadnik, D
Prufert, U
Havlik, E
Lang, S
Kvaternik, H
Flores, JA
Angelberger, P
Wanivenhaus, A
Rudiger, HW
Sinzinger, H
Citation: C. Pirich et al., Radiation synovectomy using Dy-165 ferric-hydroxide and oxidative DNA damage in patients with different types of arthritis, J NUCL MED, 41(2), 2000, pp. 250-256
Authors:
Pirker, W
Asenbaum, S
Hauk, M
Kandlhofer, S
Tauscher, J
Willeit, M
Neumeister, A
Praschak-Rieder, N
Angelberger, P
Brucke, T
Citation: W. Pirker et al., Imaging serotonin and dopamine transporters with I-123-beta-CIT SPECT: Binding kinetics and effects of normal aging, J NUCL MED, 41(1), 2000, pp. 36-44
Authors:
Virgolini, I
Kurtaran, A
Angelberger, P
Raderer, M
Havlik, E
Smith-Jones, P
Citation: I. Virgolini et al., "MAURITIUS": Tumour dose in patients with advanced carcinoma, ITAL J GAST, 31, 1999, pp. S227-S230
Authors:
Smith-Jones, PM
Bischof, C
Leimer, M
Gludovacz, D
Angelberger, P
Pangerl, T
Peck-Radosavljevic, M
Hamilton, G
Kaserer, K
Kofler, A
Schlagbauer-Wadl, H
Traub, T
Virgolini, I
Citation: Pm. Smith-jones et al., DOTA-lanreotide: A novel somatostatin analog for tumor diagnosis and therapy, ENDOCRINOL, 140(11), 1999, pp. 5136-5148
Authors:
Asenbaum, S
Pirker, W
Angelberger, P
Bencsits, G
Pruckmayer, M
Brucke, T
Citation: S. Asenbaum et al., [I-123]beta-CIT and SPECT in essential tremor and Parkinson's disease, J NEURAL TR, 105(10-12), 1998, pp. 1213-1228
Authors:
Leimer, M
Kurtaran, A
Smith-Jones, P
Raderer, M
Havlik, E
Angelberger, P
Vorbeck, F
Niederle, B
Herold, C
Virgolini, I
Citation: M. Leimer et al., Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma, J NUCL MED, 39(12), 1998, pp. 2090-2094
Risultati:
1-12
|